Telmisartan Recommended Dosage
For hypertension, start telmisartan at 40 mg once daily, with a dose range of 20-80 mg once daily based on blood pressure response; for cardiovascular risk reduction in high-risk patients ≥55 years, use 80 mg once daily. 1
Hypertension Dosing
The standard approach is straightforward:
- Starting dose: 40 mg once daily 1
- Dose range: 20-80 mg once daily, with blood pressure response being dose-related across this range 1
- Timing of effect: Most antihypertensive effect appears within 2 weeks, with maximal reduction generally attained after 4 weeks 1
- Administration: Can be taken with or without food 1
This aligns with current ESH and WHO guidelines recommending ARBs as first-line therapy for hypertension, preferably in combination with a dihydropyridine calcium channel blocker or thiazide diuretic 2, 3.
Cardiovascular Risk Reduction Dosing
For patients ≥55 years at high cardiovascular risk who cannot tolerate ACE inhibitors, use 80 mg once daily. 1 This indication requires:
- History of coronary artery disease, peripheral arterial disease, stroke, TIA, or high-risk diabetes with end-organ damage 1
- Note: Doses lower than 80 mg have not been proven effective for cardiovascular risk reduction 1
- Monitor blood pressure when initiating and adjust other antihypertensive medications as needed 1
Special Populations
Elderly Patients
No initial dosage adjustment is necessary for elderly patients. 1 Clinical trials showed no overall differences in effectiveness or safety in patients 65-74 years (19% of hypertension trials) or ≥75 years (4% of trials) compared to younger patients 1.
Renal Impairment
No initial dosage adjustment is required for patients with renal impairment, including those on hemodialysis. 1 However:
- Monitor blood pressure closely in dialysis patients as they may develop orthostatic hypotension 1
- Studies demonstrate telmisartan is safe and effective across all stages of chronic kidney disease, including severe CKD (CrCl <30 mL/min) and hemodialysis patients 4, 5
- Telmisartan is almost exclusively excreted in bile, not renally, making it particularly suitable for CKD patients 5
Hepatic Impairment
Use lower doses and uptitrate slowly in patients with biliary obstructive disorders or hepatic insufficiency. 1 This is critical because:
- Hepatic impairment increases telmisartan bioavailability significantly (2.7-3.1 fold increase in AUC) 6
- Maximum plasma concentrations increase 3.2-6.4 fold in hepatically impaired patients 6
- Total clearance is significantly reduced 6
- Consider starting with 20 mg in hepatically impaired patients given the marked increase in drug exposure 6
Important Clinical Considerations
Combination Therapy
Current guidelines strongly favor combination therapy as initial treatment for most hypertensive patients (BP ≥140/90 mmHg), preferably as single-pill combinations 2. Telmisartan combines well with:
- Dihydropyridine calcium channel blockers
- Thiazide or thiazide-like diuretics
- Never combine with another RAS blocker (ACE inhibitor + ARB) 2, 1
Volume Depletion
In volume- or salt-depleted patients (e.g., those on high-dose diuretics), symptomatic hypotension may occur after initiation. Either correct volume status first or start under close supervision with a reduced dose 1.
Contraindications
- Known hypersensitivity to telmisartan 1
- Do not co-administer with aliskiren in diabetic patients 1
- Discontinue immediately when pregnancy is detected due to fetal toxicity 1
The evidence strongly supports telmisartan's efficacy and safety profile across diverse patient populations, with its unique biliary excretion making it particularly advantageous in renal impairment, though hepatic impairment requires dose reduction.